Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) has announced the results from a 14-day oral toxicity preclinical study that showed no adverse effects from its Amanita muscaria-derived products.
The study, conducted by KGK Science, revealed no treatment-related adverse effects on animals during the study period, the company said
The next step is to move to a 90-day oral toxicity study to help pinpoint a safe and effective dose for human consumption.
READ: Psyched Wellness starts preclinical oral toxicity study of Amanita muscaria extract AME-1
During the study, Amanita muscaria extract was administered once daily for 14 consecutive days. Researchers looked at factors such as weight gain, feed consumption, hematology parameters and coagulation, and organ weights. All parameters were found to be normal during the duration of the study.
Brian Tancowny, Psyched’s scientific advisor, called the results a “major milestone” for the company’s product development.
"The 14-day and 90-day toxicological assessments of AME-1 will importantly form the foundation for all of our future preclinical studies," Tancowny said in a statement.
Psyched CEO Jeff Stevens lauded the firm’s scientific team as “doing a great job” executing on the individual studies that make up pre-clinical trials.
“I am pleased to share the positive results of our 14-day toxicity study and look forward to communicating the results from our previously announced 90-day toxicity study when available," he said
Toronto-based Psyched is developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Contact Angela at angela@proactivienvestors.com
Follow her on Twitter @AHarmantas